Actylis and Novo Nordisk Pharmatech announce a strategic partnership for the distribution of Benzalkonium Chloride in targeted European countries.
Køge, June 21, 2024
Actylis and Novo Nordisk Pharmatech have entered into an agreement for the distribution of pharmaceutical-grade Benzalkonium Chloride (BKC) to the pharmaceutical and medical device markets in Germany, Spain, Portugal, the UK, and Ireland. By combining Novo Nordisk Pharmatech’s leading position to manufacture the highest standards of pharmaceutical grade quaternary ammonium compounds (Quats), with Actylis’ expertise and infrastructures dedicated to critical raw material distribution, we aim to provide our customers with the best end-to-end service and quality.
Statement from Actylis:
Ian Jenning, SVP-President Europe at Actylis explains: ”This new agreement, built on our existing partnership in North America, represents a major opportunity for Actylis Europe to complete our pharmaceutical product portfolio while supporting the development of Novo Nordisk Pharmatech BKC for new applications”.
Statement from Novo Nordisk Pharmatech:
“We are thrilled to strengthen our collaboration with Actylis; this will extend our high standards to these fundamental European markets. We look forward to a successful partnership in the coming years,” says Samia Kappe, Chief Commercial Officer at Novo Nordisk Pharmatech.
About Actylis: Actylis is a manufacturer and global distributor of critical raw materials and ingredients for the life science industry. Our global operations include R&D facilities, GMP and non-GMP manufacturing plants, sourcing and warehousing hubs, as well as quality assurance teams and sales offices at strategic locations. Through our unique hybrid model of global distribution and manufacturing, Actylis offers a remarkable breadth of custom solutions for the supply of pharmaceutical intermediates, regulatory starting materials, APIs or excipients for small molecule manufacturing projects through clinical trials to commercial launch.
About Novo Nordisk Pharmatech:
Novo Nordisk Pharmatech is a global and leading manufacturer of pharmaceutical ingredients for the pharmaceutical and biopharmaceutical industries. The company specializes in Quats (Benzalkonium Chloride) used as active pharmaceutical ingredients (APIs) and excipients in the highest available quality standard – and Recombinant Insulin for use in cell culture media to enhance cell growth, viability, and productivity.
The products comply with the latest pharmacopoeial standards and are extensively supported by CEPs, DMFs and a comprehensive regulatory and quality assurance document package. In addition, the manufacturing site in Køge (Denmark) is audited by the Danish Medicines Agency and US FDA.
Read the FAQ about the partnership here.
https://novonordiskpharmatech.com/new-distribution-partnership-in-europe/
We are pleased to announce our attendance at the upcoming BPI Europe congress, taking place April 9-12 in Vienna.
We’ll be showcasing one of our products for the biomanufacturing industry, our Recombinant Insulin, at booth number 240. Approved by the FDA and EMA, our insulin is a key ingredient in over 100 therapeutic drugs, revolutionizing healthcare worldwide. Don’t miss the chance to learn more about our innovative solutions!
Make sure you join us at booth 240. Looking forward to seeing you there – it’s an opportunity you don’t want to miss!
https://novonordiskpharmatech.com/we-are-attending-bpi-europe-2024/
Join us at the most important vaccine event of the year – the World Vaccine Congress in Washington on April 2-4!
Are you looking for reliable partners to improve your vaccine production system? Look no further. We are here to show you how we have helped numerous vaccine developers with our top-quality products.
Join us for our talk on April 3 at 16.40 in the Influenza & Respiratory track (room 202A) and discover how Recombinant Insulin can significantly impact the manufacturing of different types of vaccines. Our talk, “Improving cell proliferation and productivity through Insulin supplementation in animal-free cell culture media,” is not to be missed!
Don’t forget to stop by our booth number 521 and chat with our team of experts who will be there to answer all your questions. Discover why we are the leading provider of Recombinant Insulin and learn how we can take your vaccine development experience to the next level.
Visit us at booth 521 from April 2 and let us be your reliable partners in vaccine development!
https://novonordiskpharmatech.com/we-are-presenting-at-world-vaccine-congress/
In many ways, 2023 has been a transformational year where we made significant progress on our Novo Nordisk Pharmatech growth strategy. Our revenue grew significantly to 880 MDKK in net sales and landed 47% higher than 2022 reflecting a good year across all products, and on top of that, we have brought three new products into our pipeline.
Read the full annual report for 2023 here.
https://novonordiskpharmatech.com/novo-nordisk-pharmatech-annual-report-2023/
We’re excited to announce our presence at this year’s BIO Asia Taiwan event, where you can meet us at booth L724 on July 27-30. We are thrilled to showcase our products and meet with industry professionals.
Our Global Product Manager, Chantale Julien, International Sales Manager for Quats products in APAC Kerina Sze Imm Soh, and Bioprocessing Sales Manager for APAC HyeJin Kim will attend, ready to answer your questions and provide insights into our high-quality Quats products and Recombinant Insulin.
If you are working within the topical segment, you could also benefit from attending our ‘Why choose a non-alcohol based antimicrobial for topicals’ presentation on the stage.
If you are in Taiwan for the event, then come by booth L724, say hello, and learn more about how our products and services can solve some of your pain points. We understand that quality and reliability are critical in biomanufacturing, and we know the importance of a trusted supplier as your partner.
We look forward to seeing you at the event!
https://novonordiskpharmatech.com/bio-asia-taiwan2023/
Which antiseptic should I use for wound care? If you plan to use an antimicrobial antiseptic in a wound care product or device, you might be considering these questions:
► Which antiseptics are both effective and safe?
► Ingredient interactions – what to be aware of?
► GMP quality or not: What is my risk threshold?
► Supplier expectations: What should I demand from my supplier?
As part of our new series of white papers discussing antimicrobial ingredient challenges, our latest publication is focusing on wound care and selecting the right antiseptic for your formulation.
Register here to access your free download.
https://novonordiskpharmatech.com/antiseptic-for-wound-care/